Navidea Biopharmaceuticals, Inc Stock (NYSEAMERICAN:NAVB)


$ 0.81
Today's Range
$0.80 - $0.85
52-Week Range
$0.72 - $2.04
Market Cap

About Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB)

(NYSEAMERICAN:NAVB) Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a collaboration agreement with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Show more

NAVB Stock Price

Statistics Highlights (NYSEAMERICAN:NAVB)

Shares Outstanding 30.30M Beta 1.39
Public Float 21.76M P/E Ratio -
% Short of Float - Dividend (Yield) -
Held by Insiders 27.62% Ex-Dividend Date
Held by Institutions 5.01% IPO Date Nov 10, 1992

NAVB Financial Summary

Dec 21 Dec 20 Dec 19
Revenue $531.51K $915.01K $657.83K
EBITDA $-11.70M $-10.65M $-10.80M
Net Income $-11.73M $-10.72M $-10.95M
Total Assets $6.64M $7.76M $4.15M
Total Cash $4.23M $2.67M $1.05M
Total Debt $453.43K $1.34M $1.07M
Mar 22 Dec 21 Sep 21
Revenue $0.00 $50.35K $96.38K
EBITDA $-2.98M $-3.70M $-2.40M
Net Income $-2.99M $-3.65M $-2.44M
Total Assets $3.60M $6.64M $8.96M
Total Cash $1.22M $4.23M $7.18M
Total Debt $ $453.43K $380.52K

NAVB Stock Price History

Navidea Biopharmaceuticals, Inc Annual Stock Price History

Year Open Close Change
2021 $1.02 $0.81 -20.70%
2021 $2.09 $1.02 -51.20%
2020 $1.23 $2.09 69.92%

Navidea Biopharmaceuticals, Inc Daily Stock Price History

Date Open High Low Close Change Volume
Jun 9, 2022 $0.89 $0.92 $0.81 $0.81 5.30% 31.60K
Jun 22, 2022 $0.75 $0.77 $0.74 $0.77 -1.38% 12.09K
Jun 13, 2022 $0.80 $0.89 $0.78 $0.78 -15.22% 42.62K


What is today's stock price of Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB)?

  • The current stock price of Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) is $0.81.
  • Today NAVB stock price opened at $0.85 after previous close of $0.81.
  • During the day, Navidea Biopharmaceuticals, Inc stock quote has varied from a low of $0.80 to a high of $0.85.

What is Navidea Biopharmaceuticals, Inc's 52-week change?

  • NAVB 52-week high stock quote is $2.04, which is 152.20% above the current share price.
  • The Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) 52-week low stock price is $0.72, which is 11.00% below the current share price.
  • Navidea Biopharmaceuticals, Inc share price volatility (52-week beta) is 1.39.

Is Navidea Biopharmaceuticals, Inc a buy?

  • According to 2 analysts, the current consensus recommendation for Navidea Biopharmaceuticals, Inc stock is "Buy" at an average rating score of 4.00 (out of 5).
  • There are currently 0 "Strong Buy", 2 "Buy", 0 "Hold", 0 "Sell", and 0 "Strong Sell" analysts recommendations for the NAVB stock.
  • The 12 month average price target forecast for NAVB stock is $6.50, representing a 703.60% increase from the current NAVB stock price of $0.81.

Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) FAQ

How Much is Navidea biopharmaceuticals, inc Worth?

Navidea biopharmaceuticals, inc's worth today based on market capitalisation is $24.56M

How much dividend does Navidea biopharmaceuticals, inc Pay?

The current annualized dividend payout for NAVB stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Navidea biopharmaceuticals, inc's "Dividend" Section

When is the next earnings date for Navidea biopharmaceuticals, inc (NYSEAMERICAN:NAVB)?

Navidea biopharmaceuticals, inc is expected to report earnings on November 08 ,2022.
View More Details on Navidea biopharmaceuticals, inc's 'Earnings' Section

What is Navidea biopharmaceuticals, inc’s Price to Earning (PE) ratio?

NAVB stock also has a Price to Sales (P/S) ratio of 60.22, a Price to Book of 8.16 and Price/Earnings to Growth (PEG) of 0.00.

What is the Navidea biopharmaceuticals, inc's ticker?

Navidea biopharmaceuticals, inc trades on the NYSE American stock market in USA under the ticker symbol "NAVB". Navidea biopharmaceuticals, inc’s stock symbol can also be displayed as "NYSEAMERICAN:NAVB".

When did NAVB go public?

Navidea biopharmaceuticals, inc completed its initial public offering (IPO) on November 10 ,1992.

Who are the owners of Navidea biopharmaceuticals, inc?

Navidea biopharmaceuticals, inc (NYSEAMERICAN:NAVB) is owned by 5.01% institutional shareholders and by 27.62% insiders. The rest is owned by the public.
Explore More Details on Navidea biopharmaceuticals, inc's “Ownership” Section

Who are the key executives of Navidea biopharmaceuticals, inc (NAVB)?

Navidea biopharmaceuticals, inc's key executive team includes the following managers:

  • Ms. Erika L. Eves, VP of Fin. & Admin. (1970)
  • Dr. Michael Stanley Rosol Ph.D., Sr. VP & Chief Medical Officer (1968)
  • Mr. Jeffrey G. Smith, VP of Operations (NA)

What is Navidea biopharmaceuticals, inc’s Sector & Industry Classification?

Navidea biopharmaceuticals, inc (NYSEAMERICAN:NAVB) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Navidea biopharmaceuticals, inc?

Currently the number of employees working for Navidea biopharmaceuticals, inc is 11.

Where are Navidea biopharmaceuticals, inc's Headquarters?

Navidea biopharmaceuticals, inc (NYSEAMERICAN:NAVB) is headquartered in OH, United States.

What are Navidea biopharmaceuticals, inc's Address and Phone Number?

Navidea biopharmaceuticals, inc’s mailing address is 4995 Bradenton Avenue, Dublin, OH, United States, 43017-3552.
The company’s phone number is 614 793 7500.

What is the official website for Navidea biopharmaceuticals, inc?

Navidea biopharmaceuticals, inc’s official website is